IMMUNOTHERAPY
Harnessing Engineered iPSC-Derived Immune Cells (Monocytes) to Eliminate Solid Tumors
Programmable, multi-functional immune cells that recognize, engage and eradicate tumors while activating broader anti-tumor immunity.
Proof of Concept
In collaboration with NTU, Singapore
From Engineering to Anti-Tumor Activity
CARTumor targetingInterleukinInterferon
Multi-gene program
Engineered iPSCs
With CAR, IL and IFN
iPSC-derived Monocytes / Macrophages
Tumor engagement
Tumor killing
Direct anti-tumor activity, e.g., CAR-mediated.
Phagocytosis
Engulf and clear tumor cells.
Antigen presentation
Activate T cells and NK cells for a broader anti-tumor response.
Key Benefits
Targeted & potent
anti-tumor activity
Multi-functional
(kill, phagocytose, activate immunity)
Programmable
(e.g., CAR, IL, IFN combinations)
Off-the-shelf & scalable
(iPSC-based)
One Engineering Platform. Multiple Immune Cell Possibilities.
Our Immunotherapy Pipeline
iPSC-derived CAR-MFor HER2-positive solid cancersIn collaboration with NTU, Singapore
Preclinical
Current stageIND EnablingClinicalCommercial
Current stageIND EnablingClinicalCommercial